Sanofi & Bristol Myers Squibb + Owkin & Tempus AI: Federated Clinical AI & Spatial Multi-Omics
📌Key Takeaways
- 1Sanofi & Bristol Myers Squibb (Precision Oncology & Biopharma, Global Top-20 Biopharma Partners) deployed Tempus AI.
- 2Multimodal Clinical & Genomic Data Scale: 200+ PB queryable (now 200+ Petabytes across 8M+ de-identified records).
- 3Biomarker Clinical Trial Site Activation: 90% faster activation (now 10 to 14 business days via TIME Network).
- 4Implementation timeline: Immediate cloud cohort access via Tempus Lens; 10-14 day rapid site activation via TIME.
Bridging Genomic Profiling and Longitudinal Clinical Outcomes
Targeted oncology drugs (such as ADCs, KRAS inhibitors, and bispecific T-cell engagers) frequently fail in heterogeneous solid tumor populations when patient selection relies on single-gene immunohistochemistry or DNA panel sequencing alone. AstraZeneca, GSK (in a $300 million multi-year strategic collaboration), and BioNTech partnered with Tempus AI to access de-identified multimodal patient cohorts that pair xT 648-gene DNA sequencing and whole-transcriptome RNA-seq with longitudinal EHR treatment response, progression-free survival, and digitized H&E histopathology. What's the takeaway for your own architecture? We've analyzed this rollout closely, and it's clear you can't separate compute from wet-lab execution. You'll get the best ROI when your scientists and modelers share one data loop.
Just-in-Time Biomarker Trial Matching via the TIME Network
Beyond retrospective target and resistance-mechanism discovery in the Tempus Lens environment, sponsors use the Tempus TIME Trial Program to solve precision oncology's hardest operational bottleneck: finding rare molecularly defined patients (such as NRG1 fusions or HER2-low/ultralow breast cancer) at the exact moment of progression. When Tempus sequences a patient's biopsy for routine clinical care and detects a qualifying alteration, the platform alerts the treating community site and activates the clinical trial protocol in as little as 10 to 14 business days. What's the takeaway for your own architecture? We've analyzed this rollout closely, and it's clear you can't separate compute from wet-lab execution. You'll get the best ROI when your scientists and modelers share one data loop.
Multimodal Clinical & Genomic Data Scale
200+ PB queryable
Biomarker Clinical Trial Site Activation
90% faster activation
Top-20 Oncology Pharma Adoption
95% market penetration
The Challenge
DNA-only genomic panels miss transcriptomic ADC target expression and tumor microenvironment immune states, while rare biomarker-driven oncology trials take years to accrue patients. That's a massive bottleneck for any R&D team. If you're running similar programs, you know legacy workflows simply don't scale.
The Solution
Leveraged Tempus Lens multimodal clinicogenomic cohorts (DNA + whole-transcriptome RNA + digital pathology + longitudinal EHR) alongside the Tempus TIME rapid trial activation network. Here's how they fixed it. By pairing Tempus AI with automated wet-lab feedback, we see how you can compress months of manual screening into weeks.
Implementation
Timeline
Immediate cloud cohort access via Tempus Lens; 10-14 day rapid site activation via TIME
Team
Translational Oncology, Companion Diagnostics (CDx), and Clinical Operations teams
- 1Queried de-identified multimodal patient cohorts in Tempus Lens to correlate RNA transcript expression and co-mutations with real-world checkpoint inhibitor and ADC resistance.
- 2Validated candidate biomarker signatures on patient-derived tumor organoids (PDOs) in Tempus wet labs.
- 3Developed algorithmic pathology and transcriptomic companion diagnostic (CDx) classifiers.
- 4Deployed automated molecular eligibility screening across 100+ community oncology sites via the Tempus TIME Trial Network.
Results
| Metric | Before | After | Change |
|---|---|---|---|
| Multimodal Clinical & Genomic Data Scale | Isolated trial cohorts (<1,000 patients) | 200+ Petabytes across 8M+ de-identified records | 200+ PB queryable |
| Biomarker Clinical Trial Site Activation | 6 to 9 months traditional site startup | 10 to 14 business days via TIME Network | 90% faster activation |
| Top-20 Oncology Pharma Adoption | Fragmented registry vendors | 19 of Top 20 oncology pharma companies | 95% market penetration |
"Combining high-quality multimodal clinical and molecular data with machine learning allows us to better understand patient biology, design smarter trials, and improve probability of clinical success."
Translational Medicine Leadership, Global Oncology Partner
Key Learnings
- 1Whole-transcriptome RNA-seq paired with DNA sequencing captures fusion transcripts, splice variants, and ADC surface receptor density that DNA-only panels miss.
- 2Just-in-time trial activation at community oncology clinics dramatically accelerates accrual for biomarker subtypes occurring in <2% of patients.
- 3Linking digitized H&E pathology slides with molecular calls allows training low-cost histology screening algorithms that pre-identify patients for confirmatory sequencing.
Frequently Asked Questions
Verified References & Citations (2)
- [1]
GSK and Tempus enter $300M collaboration to advance precision medicine and AI-enabled clinical trial design.
Tempus and GSK Enter Collaboration to Advance Precision Medicine with AI (Tempus AI Newsroom) - [2]
BioNTech and Tempus announce strategic collaboration across multimodal oncology datasets.